Cosmos Health (COSM) and Smart for Life (SMFL) Execute Letter of Intent for Strategic...
LOI Calls for the Provision of SMFL Pan-European Access and COSM North American Access for Products and Services
MIAMI and CHICAGO, Oct. 27, 2022 (GLOBE...
Smart for Life (SMFL) Featured by New to the Street
Interviews to Air on National Television Including Bloomberg and Fox Business
MIAMI, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart...
Smart For Life (SMFL) $0.37 Announces Initiation of Equity Analyst Coverage by Dawson James...
Initiates with “Buy” recommendation and $8 price target.
MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life”...
Revive Therapeutics Gains 25% on Positive FDA Comments.
The Company stated yesterday that it "has received positive comments from the FDA in regard to the Company’s request to determine and agree on...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found in Virtually all...
Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...
We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10 Price Targets....
Smart For Life to Present at The Noble Capital Markets Eighteenth Annual Investor Conference.
MIAMI, April 14, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a global leading developer, marketer,...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
As we stated earlier, Revive Therapeutics (RVVTF)...
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Early Bird Gets the Worm?
Here's...
Latest article
Everything You Need to Know on Carlin-Type Gold Deposits
Nevada is one of the world’s most productive gold-mining regions, and it’s the high-grade Carlin-type gold deposits (CTGDs) that put the Silver State on...
Fairchild (FAIR) Soars 33% on News of Large Investor Stake.
Okay that headline, while factual is a bit of 'click-bait,' so let's not get too excited!
But it is indeed excellent news.
The stock...
Replimune (REPL) $10.07. Our Analyst Sells.
Inside the Wild Ride of Replimune (REPL). We're Up And Out, With 360% Gain.
Shareholders (for now) are enjoying massive $657 million gain, in just...
